NEWS

 

Laurent Pharmaceuticals announces initiation of a Phase 1 clinical study of Fenretinide in Cystic Fibrosis

MONTREAL, QC, Canada - May 20, 2014
Laurent Pharmaceuticals Inc. announced today that the Research Institute of the McGill University Health Centre (RI-MUHC) has started enrolling patients in an investigator-initiated clinical trial evaluating the safety, tolerability and pharmacokinetics of a novel oral formulation of Fenretinide in adult subjects with Cystic Fibrosis (CF) and Pseudomonas aeruginosa lung colonization. The study will be conducted at the Montreal Chest Institute at the MUHC in Montréal, with financial support from McGill University, MSBi Valorisation and Laurent Pharmaceuticals.

Read more ...

A new orphan disease-focused company

MSBi Valorisation announces the creation of Laurent Pharmaceuticals, a new biopharmaceutical company specializing in rare diseases
 
Montreal, QC, Canada – April 22, 2013
MSBi Valorisation (MSBiV), McGill University (McGill) and the Research Institute of the McGill University Health Centre (RI-MUHC) today announced the creation of Laurent Pharmaceuticals, a start-up pharmaceutical company specializing in drug development for orphan diseases. Laurent has a lead program focusing on Fenretinide, an intensively explored but never commercialized synthetic retinoid derivative, as novel therapy for Cystic Fibrosis (CF) patients suffering from lung infection with Pseudomonas aeruginosa.
 

Events

Laurent Pharmaceuticals to participate at the NACFC 2018October 18th-20th 2018, Denver, Colorado, USA

Laurent Pharmaceuticals to participate at RESI NYC 2018November 5th 2018, New York City, USA